|
|
|
|
Frova® (frovatriptan)
Long-acting triptan (selective serotonin receptor agonist)
(Exclusive North American marketing rights licensed from Vernalis Development
Limited) |
Prophylaxis for menstrual migraine |
Supplemental New Drug Application (sNDA) filed
July 19, 2006; non-approvable letter issued
September 2007 |
EN 3267 - Rapinyl™
Oral, fast-dissolving tablet of fentanyl for sublingual administration
(Exclusive North American marketing and development rights licensed from Orexo
AB) |
Breakthrough cancer pain |
Phase III |
EN 3269 - Topical Ketoprofen Patch
(Exclusive U.S. and Canadian development and commercialization rights licensed
from ProEthic Pharmaceuticals, Inc.)
|
Localized treatment of acute pain associated with
soft-tissue injuries such as tendonitis or joint sprains and strains
|
Phase III |
EN 3285 - NAC Oral
Rinse
(Topical oral-rinse formulation) |
Oral mucositis |
Phase III |
|
EN 3270 - Transdermal Sufentanil Patch (Exclusive U.S. and Canadian
development and commercialization rights licensed from DURECT Corporation)
|
Moderate-to-severe chronic pain for up to seven days
|
Phase II |
EN 3294
(Staccato® fentanyl)
(Exclusive North American development and
commercialization rights licensed from Alexza Pharmaceuticals, Inc.)
|
Breakthrough cancer and non-cancer pain
|
Phase I |
